Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein
about
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Innovative agents in multiple myelomaStructure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideStructural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligaseDaunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia ModelLenalidomide for the treatment of relapsed and refractory multiple myeloma.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Pharmacokinetics and tissue disposition of lenalidomide in mice.Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.Future agents and treatment directions in multiple myeloma.The role of P-glycoprotein in drug resistance in multiple myeloma.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.m-TOR inhibitors and their potential role in haematological malignancies.Emerging drugs and combinations to treat multiple myeloma.Trial Watch: Lenalidomide-based immunochemotherapy.Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma.Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma.The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions
P2860
Q27004421-C4FACEE5-20C5-407A-A978-CEA86EE3D482Q27022493-335F3694-C2EA-46B6-BB77-28A22AFAFE15Q27684738-DA8DAC65-B553-4188-9BA1-51847C216EAEQ27704179-344FDDE5-D005-4FDE-907C-2B30656E65CAQ28833494-64A1726B-C84C-48B5-B33A-C952C940A574Q33403183-5E4D3E2C-7D61-4A3C-B67F-9E3738A6433CQ33410022-BAA0FB61-A0E4-44C2-A839-395EB3E59DADQ33433453-0854F6D8-6107-4F6B-8874-B35C3033E00AQ33442755-526BF982-261F-4231-A3E3-9C99D1A88E93Q34056295-97754FD6-ABCA-4520-A773-130F28B773FDQ34085747-1CB0A5BA-CB10-48FA-BE5F-73A4384E500AQ34253548-576B7964-1059-4C42-9480-3D195ED3A840Q36331493-625C5325-38BD-49D3-A97F-52974B616E9EQ36717999-097379E3-1F79-4422-BF91-27F24A4AAEBBQ37724506-35290975-1C93-430D-9EC0-090D5117221EQ38172300-43B095D9-F226-421D-A32A-6B191BAAC399Q38200143-8274406A-2602-42EA-A67D-CF452722E71AQ38413040-6DDBB83B-5CF2-46B4-BA95-0820D0BF55AAQ38545607-DE5A757C-AE9A-4BC1-8449-60264C0017E6Q38630472-0AC9AEFB-E4A4-4EFF-9889-70918B935330Q39113506-71C765B6-309C-4442-86F7-ED01FC1445A6Q41694198-5810BB78-AF29-46D5-99CB-A3B6CB2C3EF0Q42737828-0FD1B1F6-FE20-4F8B-9126-0EB0069D394CQ45356311-2F0AD451-632E-4F3C-85D9-72177D837DD8Q48203285-930190E5-7DE2-4FB0-AA72-6B09DF49AD7FQ48234027-CEBB664C-A535-4982-8CED-F4D99600E70DQ54538386-358004D2-EAD6-45E5-A375-1090C75EAD47Q57153113-AF056A88-9E63-42C8-AD3E-EC9DC020774C
P2860
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@ast
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@en
type
label
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@ast
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@en
prefLabel
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@ast
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@en
P2093
P2860
P356
P1476
Phase I trial of lenalidomide ...... interaction via P-glycoprotein
@en
P2093
Amy J Johnson
Celia L Garr
Ching-Shih Chen
Craig C Hofmeister
Darlene M Rozewski
Don M Benson
Eric H Kraut
Erinn M Hade
Flavia Pichiorri
P2860
P304
P356
10.1200/JCO.2010.32.4962
P407
P577
2011-08-08T00:00:00Z